Palisade Bio (PALI) Net Cash Flow Growth (5y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Palisade Bio | 439.25 Mn | 309.68 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -50.51% |
| Dec 31, 2025 | 407.77% |
| Sep 30, 2025 | 24.37% |
| Jun 30, 2025 | 23.65% |
| Mar 31, 2025 | -20.37% |
| Dec 31, 2024 | 23.00% |
| Sep 30, 2024 | -21.61% |
| Jun 30, 2024 | 15.38% |
| Mar 31, 2024 | 8.30% |
| Dec 31, 2023 | -124.18% |
| Sep 30, 2023 | 4.21% |
| Jun 30, 2023 | 26.06% |
| Mar 31, 2023 | -21.41% |
| Dec 31, 2022 | 7.69% |
| Sep 30, 2022 | 27.99% |
| Jun 30, 2022 | 20.21% |
| Mar 31, 2022 | -1.85% |
| Dec 31, 2021 | -18.93% |
| Sep 30, 2021 | 17.78% |
| Jun 30, 2021 | 27.34% |
| Mar 31, 2021 | -15.25% |
| Dec 31, 2020 | 66.04% |
| Sep 30, 2020 | -16.77% |
| Jun 30, 2020 | -7.16% |
| Mar 31, 2020 | 35.55% |
| Dec 31, 2019 | -42.17% |
| Sep 30, 2019 | 28.68% |
| Jun 30, 2019 | 11.15% |
| Mar 31, 2019 | -26.12% |
| Dec 31, 2018 | -34.68% |
| Sep 30, 2018 | -17.70% |
| Jun 30, 2018 | -11.98% |
| Mar 31, 2018 | -10.18% |
| Dec 31, 2017 | 0.33% |
| Sep 30, 2017 | -18.59% |
| Jun 30, 2017 | -14.58% |
| Mar 31, 2017 | -26.65% |
| Dec 31, 2016 | 48.26% |
| Sep 30, 2016 | -22.88% |
| Jun 30, 2016 | 28.17% |
| Mar 31, 2016 | 43.40% |
| Dec 31, 2015 | -29.30% |
| Sep 30, 2015 | 30.88% |